Target Corporation
TGT SP500 Consumer StaplesKursutveckling (180 dagar)
Kursutveckling vs OMX30
Fundamentala nyckeltal
AI-analys
Kort sikt (3 månader)
54/100Baserat enbart på tekniska signaler.
Lång sikt (3 år)
52/100Baserat enbart på sentiment, inga fundamenta tillgängliga.
Bortsållad av Haiku-förfilter — visas inte i topp-listan men sparas för historik.
Senaste nyheter
That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades.
That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades.
That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades.
That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades.
That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades.
Kevin Warsh insists the Federal Reserve will do whatever it takes to reduce U.S. inflation to its 2% target, but investors aren’t buying it.
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company’s 2031 sales target.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rati...
The drugmaker maintained its forecasts as oncology and rare-disease sales offset weaker revenue in China.
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
The latest update on AB Electrolux trims the central fair value estimate from SEK 50.62 to SEK 49.01, a reduction of about 3.2% in the price target. This shift lines up with more cautious analyst comm...
The latest update on AB Electrolux trims the central fair value estimate from SEK 50.62 to SEK 49.01, a reduction of about 3.2% in the price target. This shift lines up with more cautious analyst comm...
The latest update on AB Electrolux trims the central fair value estimate from SEK 50.62 to SEK 49.01, a reduction of about 3.2% in the price target. This shift lines up with more cautious analyst comm...
The latest update on AB Electrolux trims the central fair value estimate from SEK 50.62 to SEK 49.01, a reduction of about 3.2% in the price target. This shift lines up with more cautious analyst comm...
The latest update on AB Electrolux trims the central fair value estimate from SEK 50.62 to SEK 49.01, a reduction of about 3.2% in the price target. This shift lines up with more cautious analyst comm...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
Alfa Laval’s latest analyst update comes with no change to the existing price target, which keeps the current valuation view firmly in place for now. As an investor, that stability can be just as info...
Alfa Laval’s latest analyst update comes with no change to the existing price target, which keeps the current valuation view firmly in place for now. As an investor, that stability can be just as info...
Alfa Laval’s latest analyst update comes with no change to the existing price target, which keeps the current valuation view firmly in place for now. As an investor, that stability can be just as info...
Alfa Laval’s latest analyst update comes with no change to the existing price target, which keeps the current valuation view firmly in place for now. As an investor, that stability can be just as info...
Alfa Laval’s latest analyst update comes with no change to the existing price target, which keeps the current valuation view firmly in place for now. As an investor, that stability can be just as info...